The pharmaceutical blockbuster model is wobbling. And no single franchise is safe. While king Keytruda, Merck’s stalwart oncology drug, continues to rule the first half of 2025 with $15.2B in sales (Q1 $7.2B, Q2 $8.0B), its U.S. patent expiry in 2028 the single biggest loss of exclusivity event on the horizon. In the U.S., Medicare…
Supercomputer-based Bayesian approach to AI pays dividends for BPGbio
In an AI hype-filled biopharma industry, one company is taking a back-to-basics yet supercomputer-powered approach — using Bayesian analysis on massive patient datasets to guide drug discovery. The company crunches trillions of data points per patient. “It’s massive, which is why we use a supercomputer,” said Niven R. Narain, Ph.D., BPGbio CEO. The company has…